Company Overview

Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market.

Javelin’s product candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma. Our product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments.

Javelin has three late stage product candidates in development: Dyloject™ (diclofenac sodium, injectable), Rylomine™ (intranasal morphine) and PMI-150 (intranasal ketamine).

CONTACT US   JOIN US   SITE MAP
© 2006 Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.